AbbVie Inc. (ABBV) Total liabilities 2016–2025
AbbVie Inc. (ABBV) total liabilities at each fiscal year-end, per SEC filings.
$137.2BFY2025 · since FY2016: $61.5B → $137.2B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $137.2B | +4.1% |
| FY2024 | $131.8B | +6.0% |
| FY2023 | $124.4B | +2.3% |
| FY2022 | $121.6B | -7.3% |
| FY2021 | $131.1B | -4.6% |
| FY2020 | $137.5B | +41.3% |
| FY2019 | $97.3B | +43.5% |
| FY2018 | $67.8B | +3.2% |
| FY2017 | $65.7B | +6.9% |
| FY2016 | $61.5B | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More ABBV financial trends
ABBV RevenueABBV Net incomeABBV Net marginABBV Gross profitABBV Gross marginABBV Operating incomeABBV Operating marginABBV Operating cash flowABBV Free cash flowABBV Capital expendituresABBV Return on equityABBV Stock buybacksABBV Dividends paidABBV Total assetsABBV Shareholders’ equityABBV overview →